FDA, once shielded from politics, is a lobbyist target under Trump
Health secretary Robert F. Kennedy Jr. has made bold promises to eliminate industry influence from the Food and Drug Administration (FDA). However, under the Trump administration, political priorities have infiltrated the agency, creating new opportunities for lobbying efforts by the pharmaceutical industry.
According to insiders including lobbyists, advisers, FDA officials, and industry executives, the relationship between pharmaceutical companies and the administration has undergone a significant shift. Michael Abrams, a managing partner at Numerof and Associates who works with pharmaceutical clients on regulatory matters, noted that discussions about FDA decisions that were previously considered taboo are now becoming the norm in the current administration.
The injection of political considerations into FDA decision-making has raised concerns about the independence and integrity of the agency. Critics worry that industry influence may compromise the FDA’s ability to prioritize public health and safety over corporate interests.
As the pharmaceutical industry seeks to capitalize on the new political landscape, there is growing scrutiny of the interactions between companies and government officials. Transparency and accountability have become increasingly important as stakeholders seek to ensure that FDA decisions are based on scientific evidence and public health considerations rather than political or financial motives.
It is essential for the FDA to maintain its reputation as a trusted regulatory body that prioritizes the well-being of the American public. Efforts to root out industry influence and uphold the agency’s commitment to public health must remain a top priority for the health secretary and the administration as a whole.
